SWM
ABBV icon

Shakespeare Wealth Management’s AbbVie ABBV Stock Holding History

Shakespeare Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$435K Sell
1,730
-99
-5% -$21.3K 0.12% 52
2026
Q1 		$398K Sell
1,829
-182
-9% -$40.4K 0.09% 67
2025
Q4 		$459K Buy
2,011
+572
+40% +$130K 0.1% 67
2025
Q3 		$333K Buy
1,439
+20
+1% +$4.07K 0.08% 78
2025
Q2 		$263K Sell
1,419
-544
-28% -$101K 0.07% 84
2025
Q1 		$411K Buy
1,963
+9
+0.5% +$1.75K 0.11% 71
2024
Q4 		$347K Buy
1,954
+39
+2% +$7.17K 0.09% 74
2024
Q3 		$378K Buy
1,915
+10
+0.5% +$1.87K 0.1% 71
2024
Q2 		$327K Buy
1,905
+8
+0.4% +$1.32K 0.09% 72
2024
Q1 		$345K Buy
1,897
+90
+5% +$15.5K 0.1% 67
2023
Q4 		$280K Hold
1,807
– – 0.09% 70
2023
Q3 		$269K Hold
1,807
– – 0.09% 67
2023
Q2 		$243K Buy
1,807
+6
+0.3% +$880 0.08% 68
2023
Q1 		$287K Buy
1,801
+174
+11% +$26.6K 0.1% 62
2022
Q4 		$263K Buy
+1,627
New +$249K 0.1% 63
2022
Q3 		– Sell
-1,413
Closed -$218K – 68
2022
Q2 		$218K Buy
1,413
+11
+0.8% +$1.68K 0.09% 66
2022
Q1 		$227K Buy
+1,402
New +$204K 0.08% 71

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Shakespeare Wealth Management's ABBV Position: Q2 2026 in Review

Shakespeare Wealth Management reduced its AbbVie (ABBV) stake by 5.4% in Q2 2026, selling an estimated $21.3K and leaving 1,730 shares worth $435K. The position accounts for 0.12% of the portfolio, ranked #52.

Shakespeare Wealth Management first reported a position in ABBV in Q1 2022 and has held it in 17 quarters since. The position peaked at $459K in Q4 2025. 4,209 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Shakespeare Wealth Management held 1,730 shares of AbbVie worth $435K as of Q2 2026.
  • Shakespeare Wealth Management sold 99 AbbVie shares in Q2 2026, an estimated $21.3K.
  • AbbVie made up 0.12% of Shakespeare Wealth Management's portfolio in Q2 2026, its #52 holding.
  • Shakespeare Wealth Management first reported a position in AbbVie in Q1 2022 and has held it in 17 quarters since.
  • Shakespeare Wealth Management's AbbVie position peaked at $459K in Q4 2025.
  • 4,209 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Shakespeare Wealth Management's 13F filing for Q2 2026, filed 20 Jul 2026.